Pressure BioSciences, Inc. (OTCQB:PBIO) is among the many leaders in within the growth and sale of enabling excessive pressure-based devices, consumables, and associated providers for the worldwide life sciences trade. The firm was just lately within the information for the industrial launch of its contract
providers enterprise to assist its platform expertise enterprise that caters to the $200 billion biopharmaceutical market. As of as we speak, the corporate has three proprietary platform applied sciences, every of which give distinctive advantages to the life sciences trade and have extremely promising futures.
Pressure Cycling Technology – A Solid Core Business with A New Target Market
Before the December 2017 acquisition of the Barofold contract providers enterprise, PBIO was already well-known for the sale of their strain biking expertise (PCT)-based devices and associated consumables to organic analysis and manufacturing laboratories throughout the globe. The firm presently has over 300 PCT instrument programs positioned in roughly 200 educational, authorities, pharmaceutical, and biotech laboratories worldwide, which embrace the likes of Harvard, Stanford, and Cedars Sinai; the NIH, CDC, and USDA; and Genentech, Children’s Medical Research Institute (Sydney, AU), and the Westlake Institute for Advanced Study (Hangzhou, China). Also, there are over 120 impartial scientific publications highlighting some great benefits of utilizing the PCT Platform for cell lysis, pattern preparation and the characterization of biomolecules: many of those research are from world famend key opinion leaders.
With an thrilling new PCT software centered on high quality management (QC) monitoring of protein therapeutics growth and manufacturing, PBIO has just lately shifted its focus from educational analysis labs to biopharmaceutical corporations. In addition, biotechnology corporations are discovering that PBIO’s platform applied sciences are very useful in figuring out new drug targets and biomarker signatures to assist within the growth of diagnostic exams that may predict danger of illness and response to drugs. The elevated utility of PBIO’s platforms for the biotechnology and biopharmaceutical industries is anticipated to offer the corporate with substantial gross sales development within the close to time period. In truth, a few of PBIO’s latest prospects embrace massive names like Sanofi and Genentech; such corporations are identified to have very massive analysis and growth budgets with a lot shorter gross sales cycles in comparison with educational analysis amenities. Another metric value highlighting is that there are greater than 80,000 labs worldwide that would profit from PBIO’s platform applied sciences, implying an addressable market of over a billion {dollars}. This offers a sign of how quickly the top-line of PBIO’s core enterprise might probably develop if administration is ready to market its core product functions successfully to its latest goal buyer segments. In abstract, PBIO is properly positioned to develop its management place for pressure-enabled platform applied sciences and supply invaluable merchandise to analysis labs, translation facilities, and biotechnology and biopharmaceutical corporations.
The “BaroFold” Protein Therapeutics Opportunity
One of the realities of modern-day drugs is the dramatic improve in the usage of protein-based medication to deal with varied circumstances comparable to most cancers and autoimmune ailments. More and extra biopharmaceutical gamers are manufacturing these medication and the R&D exercise on this market phase is rising quickly. However, these protein therapeutics are tougher to make than small molecule medication and have are inclined to mixture or stick collectively, which might negatively have an effect on the drug’s scientific utility. There is an rising want for disaggregating these proteins; PBIO’s patented BaroFold resolution might help to deal with this downside. In truth, when the corporate acquired the huge mental property property of Barofold, Inc. in December 2017, it was to permit them to broaden their disaggregation and refolding capabilities to assist the event and manufacturing of protein therapeutics.
The contract providers provided by PBIO is named the ”BaroFold” platform; it employs the corporate’s proprietary strain expertise to disaggregate, take away or assist forestall protein aggregates from biotherapeutic drug manufacturing, thereby bettering product efficacy and security for each new-drug entities and biosimilar merchandise. These advantages are enabled by utilizing strain to carry out managed refolding of recombinant proteins into their native and most steady buildings for desired drug exercise and shelf-stability. Thus, PBIO’s “BaroFold” platform expertise cannot solely trigger the dissolution of protein aggregates, which might have a big constructive influence on the standard of protein medication by bettering protein exercise and stability, but in addition by eradicating or stopping aggregates which have undesirable immunogenic properties, comparable to immune toxicity.
The BaroFold platform also can assist biotechnology and biopharmaceutical companies to create novel protein therapeutics, speed up therapeutic protein growth, manufacture follow-on biologics, and allow life-cycle administration of protein therapeutics. Thus, this platform expertise might help PBIO’s prospects create and manufacture top quality, novel protein therapeutics at probably decrease prices of manufacturing. For instance, the usage of E.Coli micro organism for manufacturing protein therapeutics is changing into increasingly prolific, as it may be a really cost-effective method to manufacture biosimilar protein therapeutics which have misplaced their patent safety, and thus turn out to be weak to elevated competitors. However, manufacturing proteins in E. Coli has a number of technical points that may end up in elevated protein aggregation and misfolding points, highlighting the rising alternative for PBIO’s BaroFold disaggregation and refolding platform expertise. Given the rising steerage from the US FDA with respect to high quality management and growth of protein medication and the rising want for disaggregation and refolding enhancements, there may be immense alternative for PBIO’s new, proprietary options inside this massive and rising market.
Ultra Shear Technology – Pressure Bio’s Wild Card
Ultra Shear Technology (UST) is the most recent expertise developed by the corporate. This novel platform combines ultra-high strain with a proprietary dynamic valve to create intense shearing forces that end result within the creation of nanoemulsions when processing oil-based options. Specifically, the UST platform successfully makes use of strain as excessive as 60,000 psi to shear oil drops right down to very small droplet sizes (i.e., below 100 nanometers), such that these oil droplets can successfully combine with water, ensuing within the creation of high-quality, steady nanoemulsion options. As oil-based options are poorly absorbed by the physique and may be difficult to fabricate, PBIO’s UST platform has a number of, probably invaluable product software throughout varied industries, comparable to CBD merchandise and different nutraceuticals, cosmetics and topicals, food and drinks, and new drug supply functions. A very good instance for the usage of the UST expertise is for the preparation of upper high quality, homogenized, prolonged shelf-life or room temperature steady low-acid liquid meals that can’t be successfully preserved utilizing present non-thermal applied sciences, comparable to milk and different dairy merchandise.
Although this platform might not generate product revenues in 2019, it has the potential to start contributing to the top-line of PBIO very quickly by way of the licensing of mental property or a three way partnership. In addition, the UST platform helps handle a number of very massive and rising market alternatives which might be within the billions to a whole bunch of billions of {dollars} yearly.
Conclusion
Breaking paradigms which have existed for many years with expertise so new it has hardly ever been used within the life sciences discipline earlier than is a tough activity, to say the least. It is due to this fact not all shocking that it has taken PBIO virtually a decade to get to the place it’s as we speak. Regardless, the corporate has executed an incredible job of growing novel, pressure-based platform applied sciences that handle massive and rising market alternatives, as they educated customers on the distinctive advantages of their proprietary, excessive pressure-based platform applied sciences to deal with unmet wants for the life sciences and biotechnology industries. They started off on the analysis aspect, have moved in the direction of growth and high quality management functions in biopharmaceutical corporations, and with the brand new vertical of nanoemulsion options, they’ve now entered the manufacturing aspect for all times sciences.
The synergies between the corporate’s verticals is unquestionable as its PCT devices have a powerful use in disaggregation and refolding of proteins and there are stable cross-selling alternative for the corporate with respect to each these verticals. There can be the big and quickly rising CBD market that’s addressable by way of the UST platform and formulation options supplied by PBIO.
The nature of options supplied by PBIO is kind of distinctive and faces few direct opponents. The major competitors the corporate faces is within the type of conventional reagents and strategies, homogenizers and different inferior platforms which might be sure to get replaced by technological developments, particularly for the manufacturing of high-quality nanoemulsion options.
Overall, it may be safely concluded that PBIO is properly on the trail to a shiny future within the life sciences and different industries.
LEGAL DISCLAIMER
Except for the historic data introduced herein, issues mentioned on this article include forward-looking statements which might be topic to sure dangers and uncertainties that would trigger precise outcomes to vary materially from any future outcomes, efficiency or achievements expressed or implied by such statements. Salesparq, LLC which owns SmallcapsDaily.com isn’t registered with any monetary or securities regulatory authority and doesn’t present nor claims to offer funding recommendation or suggestions to readers of this launch. Salesparq, LLC, which owns SmallcapsDaily.com, could also be compensated for its providers within the type of cash-based compensation for the businesses it writes about. For making particular funding selections, readers ought to search their very own recommendation. Pursuant to an settlement between TraDigital IR and Salesparq, LLC, which owns SmallcapsDaily.com, we had been employed for a interval from 3/20/2019 – 3/31/2019 to publicly disseminate details about Pressure BioSciences Inc., together with on the Website, and/or different media together with Facebook and Twitter. We had been paid $2,000 (CASH) for & had been paid “0” shares of restricted frequent shares. SmallcapsDaily also own Zero personal zero shares of Pressure BioSciences, Inc. We don’t intend to purchase or promote extra shares of Pressure BioSciences, Inc. within the open market at any time, together with earlier than, throughout or after the Website and Information, present public dissemination of favorable Information. Please learn our full disclaimer right here: https://smallcapsdaily.com/disclaimer/